Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG). (April 2020)

• Record Type: Journal Article
• Authors: Graeter, Stefanie; Simon, Hans-Uwe; von Gunten, Stephan
• Is Part Of: Pharmacological research. Volume 154(2020)
• Publication Date: 2020-04
• Subjects: Intravenous immunoglobulin -- IVIG -- High-dose IVIG -- Immunomodulation -- FAS -- Siglec-8 -- Siglec-9 -- Granulocytes -- Neutrophils -- Eosinophils; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2019.02.007
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Granulocytes are key effector cells of the innate immune system that cause substantial by-stander tissue damage in a broad range of inflammatory disorders. Specific antibodies with the potential to regulate granulocyte survival are present in polyclonal intravenous immunoglobulin (IVIG) preparations and may contribute to the anti-inflammatory effects of high-dose IVIG therapy. Here, we discuss idiosyncratic characteristics of antibodies to FAS and Siglecs contained in IVIG pertaining to granulocyte death regulation and highlight implications for research and clinical practice.